-
公开(公告)号:US20090270444A1
公开(公告)日:2009-10-29
申请号:US11718892
申请日:2005-11-17
IPC分类号: A61K31/4375 , C07D471/04 , A61P37/08
CPC分类号: C07D471/04
摘要: There are provided according to the invention novel compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein: R1 is phenyl which may be unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, C1-2alkoxy-, —CN; phenyl fused to a 5-membered saturated ring containing one oxygen atom; pyridinyl which may be unsubstituted or substituted by one or two substituents selected from fluorine or chlorine; or C-linked pyrazolyl which may be unsubstituted or substituted by the substituent C1-2alkyl; R2 is C1-4alkyl; R3 is C1-2alkyl; and n is 0, 1 or 2.
摘要翻译: 根据本发明,提供新的式(I)化合物及其药学上可接受的盐和溶剂化物,其中:R1是可以是未取代的或被一个或两个选自氟,氯,C 1-2烷氧基 - , - CN; 与含有一个氧原子的5元饱和环稠合的苯基; 吡啶基,其可以是未取代的或被一个或两个选自氟或氯的取代基取代; 或C连接的吡唑基,其可以是未取代的或被取代基C 1-2烷基取代; R2是C1-4烷基; R3是C1-2烷基; n为0,1或2。
-
公开(公告)号:US20090312325A1
公开(公告)日:2009-12-17
申请号:US12474324
申请日:2009-05-29
申请人: Ian Robert Baldwin , Michael David Barker , Anthony William Dean , Colin David Eldred , Brian Evans , Sharon Lisa Gough , Stephen Barry Guntrip , Julie Nicole Hamblin , Stuart Holman , Paul Jones , Mika Kristian Lindvall , Christopher James Lunniss , Tracy Jane Redfern , Alison Judith Redgrave , John Edward Robinson , Michael Woodrow
发明人: Ian Robert Baldwin , Michael David Barker , Anthony William Dean , Colin David Eldred , Brian Evans , Sharon Lisa Gough , Stephen Barry Guntrip , Julie Nicole Hamblin , Stuart Holman , Paul Jones , Mika Kristian Lindvall , Christopher James Lunniss , Tracy Jane Redfern , Alison Judith Redgrave , John Edward Robinson , Michael Woodrow
IPC分类号: A61K31/4709 , C07D401/12 , C07D417/12 , C07D403/12 , C07D215/38 , A61K31/47 , A61K31/5377 , A61P29/00 , A61P37/08
CPC分类号: C07D401/12 , C07D215/54 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D453/02
摘要: There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要翻译: 根据本发明提供新的式(I)化合物或其药学上可接受的盐,其中R1,R2,R19,R20和R34如说明书中所述,其制备方法,含有它们的制剂及其在 治疗炎症性疾病。
-
公开(公告)号:US20080146563A1
公开(公告)日:2008-06-19
申请号:US11908188
申请日:2006-03-16
IPC分类号: A61K31/5377 , C07D221/04 , A61K31/4375 , A61K31/496 , A61P37/08 , A61P29/00 , C07D295/00
CPC分类号: C07D471/04
摘要: There are provided according to the invention novel compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein R1 is selected from the group consisting of C1-4alkyl, C4-6cycloalkyl(CH2)m—, methoxyC2-4alkyl, HOCH2CH2—, R3(O)2S(CH2)2—, R5R4NCO(CH2)n—, and heterocyclyl(CH2)m— wherein any nitrogen heteroatom of the heterocyclyl radical may be unsubstituted or substituted by methyl; R2 is hydrogen or methyl; R3 is methyl or NH2; R4-5 independently represent methyl, m is 0, 1 or 2; and n is 1 or 2; or R1 and R2 together with the nitrogen atom to which they are attached may form a heterocyclyl ring, which may be unsubstituted or substituted by one or two substituents selected from the group consisting of; methyl, ═O and (CH3)2N—.
摘要翻译: 根据本发明提供新的式(I)化合物及其药学上可接受的盐和溶剂合物:其中R 1选自C 1-4烷基, 烷基,C 4-6环烷基(CH 2 CH 2)m - ,甲氧基C 2-4烷基, (O)2 S 2(CH 2)2 - - - - (CH 2) R 2,R 5,R 5,R 5,N 2,N 2, 和杂环基(CH 2 CH 2)m - ,其中杂环基的任何氮杂原子可以是未取代的或被甲基取代; R 2是氢或甲基; R 3是甲基或NH 2; R 4-5独立地表示甲基,m是0,1或2; n为1或2; 或R 1和R 2与它们所连接的氮原子一起可以形成杂环基环,其可以是未取代的或被一个或两个选自以下的取代基取代: 组成; 甲基,-O和(CH 3)2 N - 。
-
公开(公告)号:US07566786B2
公开(公告)日:2009-07-28
申请号:US10557079
申请日:2004-05-19
申请人: Ian Robert Baldwin , Michael David Barker , Anthony William Dean , Colin David Eldred , Brian Evans , Sharon Lisa Gough , Stephen Barry Guntrip , Julie Nicole Hamblin , Stuart Holman , Paul Jones , Mika Kristian Lindvall , Christopher James Lunniss , Tracy Jane Redfern , Alison Judith Redgrave , John Edward Robinson , Michael Woodrow
发明人: Ian Robert Baldwin , Michael David Barker , Anthony William Dean , Colin David Eldred , Brian Evans , Sharon Lisa Gough , Stephen Barry Guntrip , Julie Nicole Hamblin , Stuart Holman , Paul Jones , Mika Kristian Lindvall , Christopher James Lunniss , Tracy Jane Redfern , Alison Judith Redgrave , John Edward Robinson , Michael Woodrow
IPC分类号: C07D215/38 , C07D215/44
CPC分类号: C07D401/12 , C07D215/54 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D453/02
摘要: There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要翻译: 根据本发明提供新的式(I)化合物或其药学上可接受的盐,其中R1,R2,R19,R20和R34如说明书中所述,其制备方法,含有它们的制剂及其在 治疗炎症性疾病。
-
公开(公告)号:US20110039889A1
公开(公告)日:2011-02-17
申请号:US12989700
申请日:2009-04-29
IPC分类号: A61K31/4709 , C07D413/10 , C07D413/14 , A61P19/02
CPC分类号: C07D413/04 , C07D413/14
摘要: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
摘要翻译: 本发明涉及具有药理活性的新型恶二唑衍生物,其制备方法,含有它们的药物组合物及其在治疗各种病症中的用途。
-
公开(公告)号:US20090074675A1
公开(公告)日:2009-03-19
申请号:US11910935
申请日:2006-04-12
申请人: Colin David Eldred , David House , Graham George Adam Inglis , Simon John Fawcett MacDonald , Philip Alan Skone
发明人: Colin David Eldred , David House , Graham George Adam Inglis , Simon John Fawcett MacDonald , Philip Alan Skone
IPC分类号: A61K9/12 , C07D401/04 , A61K31/4439
CPC分类号: C07D405/14 , C07D231/56 , C07D401/04 , C07D405/12
摘要: A compound of formula (I): wherein A1 represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; X represents —C(R3)— or nitrogen; when X represents —C(R3)—, R2 represents hydrogen and R1 represents fluorine, R3 represents hydrogen or fluorine, when X represents —C(R3)— and R2 and R1 each represent hydrogen, R3 represents hydrogen, hydroxy, methoxy or fluorine, when X represents —C(R3)— and R2 represents hydroxy, methoxy, —CO2CH3 or —CO2CH2CH3, R1 and R3 each represent hydrogen, when X represents nitrogen, R1 and R2 each represent hydrogen; and Y represents H or methyl; or a physiologically functional derivative thereof.
摘要翻译: 式(I)的化合物:其中A1表示2,3-二氢-1-苯并呋喃-7-基,5-氟-2-甲氧基 - 苯基或5-氟-2-羟基 - 苯基; X表示-C(R 3) - 或氮; 当X表示-C(R3) - 时,R2表示氢,R1表示氟,R3表示氢或氟,当X表示-C(R3) - 且R2和R1各自表示氢时,R3表示氢,羟基,甲氧基或氟 当X表示-C(R 3) - 且R 2表示羟基,甲氧基,-CO 2 CH 3或-CO 2 CH 2 CH 3时,R 1和R 3各自表示氢,当X表示氮时,R 1和R 2各自表示氢; Y表示H或甲基; 或其生理功能衍生物。
-
公开(公告)号:US06492348B1
公开(公告)日:2002-12-10
申请号:US09736018
申请日:2001-03-06
申请人: David Edmund Bays , Richard Peter Charles Cousins , Hazel Joan Dyke , Colin David Eldred , Brian David Judkins , Martin Pass , Andrew Michael Kenneth Pennell
发明人: David Edmund Bays , Richard Peter Charles Cousins , Hazel Joan Dyke , Colin David Eldred , Brian David Judkins , Martin Pass , Andrew Michael Kenneth Pennell
IPC分类号: A61K3170
CPC分类号: C07D473/00 , C07H19/16
摘要: A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.
摘要翻译: 作为腺苷A1受体的激动剂的式(I)化合物,其中Y,Z和W表示杂原子,以及其盐和溶剂化物,特别是用于治疗的生理学上可接受的溶剂合物及其盐。
-
公开(公告)号:US08093281B2
公开(公告)日:2012-01-10
申请号:US11910935
申请日:2006-04-12
申请人: Colin David Eldred , David House , Graham George Adam Inglis , Simon John Fawcett MacDonald , Philip Alan Skone
发明人: Colin David Eldred , David House , Graham George Adam Inglis , Simon John Fawcett MacDonald , Philip Alan Skone
IPC分类号: A61K31/416 , C07D231/56
CPC分类号: C07D405/14 , C07D231/56 , C07D401/04 , C07D405/12
摘要: A compound of formula (I): wherein A1 represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; X represents —C(R3)— or nitrogen; when X represents —C(R3)—, R2 represents hydrogen and R1 represents fluorine, R3 represents hydrogen or fluorine, when X represents —C(R3)— and R2 and R1 each represent hydrogen, R3 represents hydrogen, hydroxy, methoxy or fluorine, when X represents —C(R3)— and R2 represents hydroxy, methoxy, —CO2CH3 or —CO2CH2CH3, R1 and R3 each represent hydrogen, when X represents nitrogen, R1 and R2 each represent hydrogen; and Y represents H or methyl; or a physiologically functional derivative thereof.
摘要翻译: 式(I)的化合物:其中A1表示2,3-二氢-1-苯并呋喃-7-基,5-氟-2-甲氧基 - 苯基或5-氟-2-羟基 - 苯基; X表示-C(R 3) - 或氮; 当X表示-C(R3) - 时,R2表示氢,R1表示氟,R3表示氢或氟,当X表示-C(R3) - 且R2和R1各自表示氢时,R3表示氢,羟基,甲氧基或氟 当X表示-C(R 3) - 且R 2表示羟基,甲氧基,-CO 2 CH 3或-CO 2 CH 2 CH 3时,R 1和R 3各自表示氢,当X表示氮时,R 1和R 2各自表示氢; Y表示H或甲基; 或其生理功能衍生物。
-
公开(公告)号:US06740644B2
公开(公告)日:2004-05-25
申请号:US10373064
申请日:2003-02-26
IPC分类号: A61K3170
摘要: A compound of formula (I), wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3alkyl, R2 represents C1-3alkyl, R1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C1-3alkyl, trifluoromethyl, nitro, cyano, —CO2Rc, —CONRcRd, —CORc, —SORe, —SO2Re, —SO3H, —SO2NRcRd, —ORc, —NHSO2Re, —NHCORc and —NRcRd; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine A1 receptor.
摘要翻译: 式(I)的化合物,其中R 2表示C 1-3烷基,卤素或氢; R 3表示1-6个碳原子的直链或支链烷基; 条件是当R 3表示C 1-3烷基时,R 2表示C 1-3烷基,R 1不能表示任选被一个或多个选自卤素,C 1-3烷基,三氟甲基,硝基, 氰基,-CO 2 R c,-CONR c R d,-COR c,-SOR e,-SO 2 R e,-SO 3 H,-SO 2 NR c R d, OR c,-NHSO 2 R e,-NHCOR c和-NR c R d; 特别是其生理上可接受的溶剂合物及其盐。 这些化合物是腺苷A1受体的激动剂。
-
公开(公告)号:US06544960B1
公开(公告)日:2003-04-08
申请号:US09530575
申请日:2000-06-15
IPC分类号: A61K3170
摘要: A compound of formula (I), wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3alkyl, R2 represents C1-3alkyl, R1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C1-3alkyl, trifluoromethyl, nitro, cyano, —CO2Rc, —CONRcRd, —CORc, —SORe, SO2Re, —SO3H, —SO2NRcRd, —ORc, —NHSO2Re, —NHCORc and —NRcRd; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine Al receptor.
摘要翻译: 式(I)的化合物,其中R 2表示C 1-3烷基,卤素或氢; R3表示1-6个碳原子的直链或支链烷基; 条件是当R 3表示C 1-3烷基时,R 2表示C 1-3烷基,R 1不能表示任选被一个或多个选自卤素,C 1-3烷基,三氟甲基,硝基,氰基,-CO 2 R c,-CONRc R d, CORc,-SORe,SO2Re,-SO3H,-SO2NRcRd,-ORc,-NHSO2Re,-NHCORc和-NRcRd; 特别是其生理上可接受的溶剂合物及其盐。 这些化合物是腺苷A1受体的激动剂。
-
-
-
-
-
-
-
-
-